Get the Stockscreener App
1.65
1.79%
-0.03
After Hours:
1.65
Esperion Therapeutics Inc stock is traded at $1.65, with a volume of 2.78M.
It is down -1.79% in the last 24 hours and down -9.84% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$1.68
Open:
$1.68
24h Volume:
2.78M
Relative Volume:
0.53
Market Cap:
$311.66M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.5851
EPS:
-2.82
Net Cash Flow:
$-135.49M
1W Performance:
+1.23%
1M Performance:
-9.84%
6M Performance:
-38.43%
1Y Performance:
+68.37%
1-Day Range:
$1.63
$1.74
1-Week Range:
$1.60
$1.74
52-Week Range:
$0.70
$3.40
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Drops By 5.8% - MarketBeat
Renaissance Technologies LLC Sells 694,600 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - Defense World
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily
ESH Acquisition Corp. (NASDAQ:ESHA) Shares Bought by Berkley W R Corp - Defense World
What's Going On With Seelos Therapeutics Stock Tuesday? - Benzinga
Great Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Great Point Partners LLC - MarketBeat
New Pill Cuts Cholesterol and Heart Attacks - Greek Reporter
What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News
Atopic dermatitis: New drug significantly improves symptoms - Medical News Today
How does ESAB Corp (ESAB) change from a tortoise to a hare? - SETE News
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd - Defense World
XTX Topco Ltd Has $810,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Espey Mfg. & Electronics (NYSEAMERICAN:ESP) Receives New Coverage from Analysts at StockNews.com - Defense World
Inspire Investing LLC Invests $758,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESAB Co. (NYSE:ESAB) Shares Sold by Granite Investment Partners LLC - Defense World
Bank of New York Mellon Corp Acquires 555,382 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
18,727 Shares in ESAB Co. (NYSE:ESAB) Bought by Seven Eight Capital LP - Defense World
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy" - MarketBeat
Espey Mfg. & Electronics Corp. (NYSEAMERICAN:ESP) Raises Dividend to $0.25 Per Share - Defense World
Esperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.com - Defense World
ESH Acquisition Corp. (NASDAQ:ESHA) Short Interest Up 6.8% in August - Defense World
Exicure Shares More Than Double After Nasdaq Listing Extension - MarketWatch
Esperion CEO Sheldon Koenig sells shares worth over $26k By Investing.com - Investing.com Canada
Esperion Therapeutics exec sells over $4,600 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics exec sells over $4,600 in stock - Investing.com
Esperion CEO Sheldon Koenig sells shares worth over $26k - Investing.com
Here’s What Pulled Back ESAB Corporation (ESAB) - Yahoo Finance
Bokf Na Purchases Shares of 11,905 Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics exec sells over $4,600 in stock By Investing.com - Investing.com Canada
BofA Securities Downgrades Esperion Therapeutics Inc. (ESPR) to an Underperform from a Neutral - Knox Daily
Stock Performance Spotlight: Esperion Therapeutics Inc. (ESPR) Ends the Day at 1.76, Down by -7.85 - The Dwinnex
Esperion Therapeutics Inc. (ESPR) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Principal Financial Group Inc. Sells 8,721 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Hyperlipidemia Market to Show Remarkable Growth Trends from - openPR
Esperion Therapeutics Inc. (ESPR) is looking forward to a strong quarter - SETE News
Understanding ESPR stock ratios for better investment decisions - US Post News
National Bank of Canada FI Raises Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? - Yahoo Finance
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by StockNews.com - Defense World
Esperion Gets FDA Phase III Go-Ahead Without CVOT - Scrip
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference - GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference - StockTitan
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):